• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重症肌无力患者参与研究委员会的设计及早期见解

Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council.

作者信息

Geonnotti Gabrielle, Pesa Jacqueline, Peters Wesley, Taylor Melina, Choudhry Zia, Falope Oluyemisi, Price Marquetta, Baxter Lucy, West Bruce, Shea Lisa

机构信息

Janssen Scientific Affairs, LLC Titusville New Jersey USA.

Evidera Wilmington North Carolina USA.

出版信息

Health Sci Rep. 2024 Dec 17;7(12):e70230. doi: 10.1002/hsr2.70230. eCollection 2024 Dec.

DOI:10.1002/hsr2.70230
PMID:39698529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11652384/
Abstract

BACKGROUND AND AIMS

An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).

METHODS

US-based adults with gMG and caregivers of patients with gMG participated in a Patient Engagement Research Council between August 2022 and January 2023. The study consisted of a 15-min prework survey, followed by virtual focus groups facilitated using a semi-structured interview guide. Data concepts were identified using conversational analysis and by direct observation. All transcripts were coded based on concepts using a qualitative research analysis program (MaxQDA).

RESULTS

16 participants (13 patients, three caregivers) were recruited. Participants reported impact on daily activities, fatigue, and psychosocial problems. Many participants experienced delayed diagnosis and difficulty accessing specialist care. Participants described multiple barriers related to their gMG, including barriers to treatment, access-related issues, and communication disconnect between patients and healthcare professionals. Achieving stable disease was the most important goal. There was a preference for the autonomy of self-administered medications at home versus infusions. Study insights led to recommendations to guide patient and healthcare professional education.

CONCLUSION

The study illustrates the need to improve access to specialist care, achieve earlier diagnosis, prioritize patients' preferences in disease management, and develop treatments that improve outcomes without additional burden.

PATIENT OR PUBLIC CONTRIBUTION

The data collected in this study was provided by the focus group participants, which included patients and caregivers of those with myasthenia gravis.

摘要

背景与目的

开展了一项探索性焦点小组研究,以更好地了解全身型重症肌无力(gMG)患者的需求。

方法

2022年8月至2023年1月期间,美国的gMG成年患者及gMG患者的照护者参与了患者参与研究委员会。该研究包括一项15分钟的前期调查,随后是使用半结构化访谈指南进行的虚拟焦点小组讨论。通过对话分析和直接观察确定数据概念。所有转录本均使用定性研究分析程序(MaxQDA)基于概念进行编码。

结果

招募了16名参与者(13名患者,3名照护者)。参与者报告了对日常活动、疲劳和心理社会问题的影响。许多参与者经历了诊断延迟和获得专科护理的困难。参与者描述了与他们的gMG相关的多个障碍,包括治疗障碍、与获得医疗服务相关的问题以及患者与医疗保健专业人员之间的沟通脱节。实现疾病稳定是最重要的目标。相比于输液,患者更倾向于在家自行给药的自主性。研究见解促成了指导患者和医疗保健专业人员教育的建议。

结论

该研究表明需要改善专科护理的可及性、实现更早诊断、在疾病管理中优先考虑患者的偏好,并开发在不增加额外负担的情况下改善治疗效果的疗法。

患者或公众贡献

本研究收集的数据由焦点小组参与者提供,其中包括重症肌无力患者及其照护者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/5512235253ac/HSR2-7-e70230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/66d6a7949cae/HSR2-7-e70230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/4ac4f6a607c1/HSR2-7-e70230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/5512235253ac/HSR2-7-e70230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/66d6a7949cae/HSR2-7-e70230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/4ac4f6a607c1/HSR2-7-e70230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2615/11652384/5512235253ac/HSR2-7-e70230-g003.jpg

相似文献

1
Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council.重症肌无力患者参与研究委员会的设计及早期见解
Health Sci Rep. 2024 Dec 17;7(12):e70230. doi: 10.1002/hsr2.70230. eCollection 2024 Dec.
2
Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.从患者角度理解重症肌无力的症状负担及影响:一项定性研究
Neurol Ther. 2023 Feb;12(1):107-128. doi: 10.1007/s40120-022-00408-x. Epub 2022 Nov 2.
3
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.罗扎诺利昔单抗治疗肌肉特异性酪氨酸激酶自身抗体阳性全身型重症肌无力患者的疗效和安全性:随机、双盲、安慰剂对照、适应性III期MycarinG研究的亚组分析
Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241273036. doi: 10.1177/17562864241273036. eCollection 2024.
4
Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs.社会决定因素对泛发性重症肌无力患者的影响及其对患者支持计划的启示。
Front Public Health. 2023 May 19;11:1147489. doi: 10.3389/fpubh.2023.1147489. eCollection 2023.
5
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.评估ravulizumab或efgartigimod对重症肌无力症状的控制:两种不同治疗方法的患者体验评估
Curr Med Res Opin. 2025 May;41(5):817-827. doi: 10.1080/03007995.2025.2497906. Epub 2025 May 24.
6
Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.美国全身性重症肌无力(MG)的经济负担,以及常见合并症和急性 MG 事件的影响。
Curr Med Res Opin. 2024 Jul;40(7):1145-1153. doi: 10.1080/03007995.2024.2353381. Epub 2024 May 24.
7
The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges.患有全身性重症肌无力且面临健康社会决定因素挑战的个人所承受的经济负担。
Front Public Health. 2023 Sep 12;11:1247931. doi: 10.3389/fpubh.2023.1247931. eCollection 2023.
8
Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity.重症肌无力患者的日常生活体验:一项质性研究及测评工具的内容效度评估
Neurol Ther. 2023 Dec;12(6):2079-2099. doi: 10.1007/s40120-023-00544-y. Epub 2023 Sep 25.
9
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.环磷酰胺在全身型重症肌无力患者中的长期安全性:3期MycarinG研究及开放标签扩展研究的结果
J Neuromuscul Dis. 2025 Mar;12(2):231-243. doi: 10.1177/22143602241308181. Epub 2025 Mar 4.
10
Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes.乙酰胆碱受体抗体阳性全身型重症肌无力各亚型中艾加莫德治疗反应的模式及预测因素
Ther Adv Neurol Disord. 2025 Feb 18;18:17562864251319656. doi: 10.1177/17562864251319656. eCollection 2025.

本文引用的文献

1
Myasthenia Gravis Disease Burden and Its Impact on Satisfaction with Life: A Qualitative Survey of Patients' Perspectives in Japan.重症肌无力的疾病负担及其对生活满意度的影响:日本患者观点的定性调查
Neurol Ther. 2024 Aug;13(4):1099-1113. doi: 10.1007/s40120-024-00617-6. Epub 2024 May 15.
2
Patient perceptions of copay card utilization and policies.患者对自付费用卡使用情况及政策的认知。
J Mark Access Health Policy. 2023 Sep 7;11(1):2254586. doi: 10.1080/20016689.2023.2254586. eCollection 2023.
3
Evaluation of the Quality of Life of Patients with Myasthenia Gravis in Greece.
希腊重症肌无力患者生活质量评估
J Pers Med. 2023 Jul 12;13(7):1130. doi: 10.3390/jpm13071130.
4
Myasthenic crisis.肌无力危象。
Muscle Nerve. 2023 Jul;68(1):8-19. doi: 10.1002/mus.27832. Epub 2023 Apr 28.
5
Mental health in myasthenia gravis patients and its impact on caregiver burden.重症肌无力患者的心理健康及其对照顾者负担的影响。
Sci Rep. 2022 Nov 11;12(1):19275. doi: 10.1038/s41598-022-22078-3.
6
Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.从患者角度理解重症肌无力的症状负担及影响:一项定性研究
Neurol Ther. 2023 Feb;12(1):107-128. doi: 10.1007/s40120-022-00408-x. Epub 2022 Nov 2.
7
Myasthenia gravis in clinical practice.临床实践中的重症肌无力。
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):257-265. doi: 10.1590/0004-282X-ANP-2022-S105.
8
Improving diversity in study participation: Patient perspectives on barriers, racial differences and the role of communities.提高研究参与多样性:患者对障碍、种族差异和社区作用的看法。
Health Expect. 2022 Aug;25(4):1979-1987. doi: 10.1111/hex.13554. Epub 2022 Jun 28.
9
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.全身性重症肌无力的药物治疗:特别关注新型生物制剂。
Drugs. 2022 Jun;82(8):865-887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31.
10
The humanistic burden of myasthenia gravis: A systematic literature review.重症肌无力的人文负担:系统文献回顾。
J Neurol Sci. 2022 Jun 15;437:120268. doi: 10.1016/j.jns.2022.120268. Epub 2022 Apr 21.